PT-141

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan II with a molecular weight of approximately 1,025.2 Da and selective agonist activity at the MC3R and MC4R melanocortin receptor subtypes expressed in the hypothalamus, limbic system, and brainstem — acting through a CNS-direct mechanism independent of peripheral nitric oxide pathways.

Originally developed for studying central melanocortin receptor pathways, PT-141 has been studied extensively for its ability to modulate hypothalamic circuit activity, dopaminergic neurotransmission in the mesolimbic pathway, and CNS-mediated autonomic regulation — with research demonstrating its effects on MC3R/MC4R-mediated downstream signaling, dopamine release in the nucleus accumbens, and hypothalamic regulation of autonomic physiological responses in preclinical models.

Research has focused on PT-141’s role in hypothalamic melanocortin circuit modulation, autonomic nervous system regulation, and dopaminergic pathway interactions — with its CNS-direct mechanism and defined receptor selectivity profile making it a valuable pharmacological tool for studying MC3R/MC4R-mediated signaling alongside compounds such as Semax and Selank. For further reading see: Melanocortin receptor pathway research (PubMed).

Specifications:

• Purity: ≥99% (HPLC verified)
• Form: Lyophilized powder
• Storage: −20°C

For Research Use Only.